Prolonged profound abciximab associated immune thrombocytopenia complicated by transient multispecific platelet antibodies.
case_report · Level V
Where this comes from
- Record sourced from PubMed, PMID 15310724.
- Also identified by PMC identifier 1768465.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Patients receiving abciximab occasionally develop transient severe thrombocytopenia within a few hours of receiving the drug. Thrombocytopenia has been reported to resolve within 10 days of abciximab administration, but in this case profound thrombocytopenia lasted 21 days before a slow spontaneous recovery. Management was complicated by the presence of HLA antibodies and the transient production of antibodies directed at major platelet glycoproteins IIb/IIIa, Ib/IX, and Ia/IIa. The patient remained refractory to platelet transfusion and two courses of intravenous gammaglobulin for the duration of her admission.
Medical subject headings
- Antibodies, Monoclonal
- Autoantibodies
- Autoimmune Diseases
- Blood Platelets
- Immunoglobulin Fab Fragments
- Platelet Aggregation Inhibitors
- Thrombocytopenia